Philip S. Low, MD

Dr.Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C.Corley Distinguished Professor of Chemistry at Purdue University.

Dr. Low has devoted over >45 years to exploring novel drugs for treatment of human diseases, characterizing the structure of the human red blood cell membrane, and defining signal transduction pathways in plants.

He has published >450 scientific articles and has >75 US patents/patents pending.

Eight drugs stemming from his research are undergoing human clinical trials in the areas of: i) tumor-targeted drugs for the imaging and therapy of cancer, ii) a new therapy for malaria, iii) a novel treatment for sickle cell disease, iv) tumor-targeted fluorescent dyes for image-guided surgery of cancer, and v) novel imaging and therapeutic agents for inflammatory and autoimmune diseases.

Six companies (Endocyte Inc., OnTarget Laboratories Inc., Novosteo Inc., Umoja Biopharma Inc., Erythro Cure Inc. and HuLow LLC) have been founded to commercialize these discoveries.

Dr. Low has received an NIH MERIT Award, the American Chemical Society’s Award for Cancer Research (Sosnovsky Award), the American Association for Cancer Research’s (AACR) Award for Outstanding Chemistry in Cancer Research, both of Purdue’s awards for outstanding research (McCoy and Sigma Xi Awards), the University’s highest career achievement award (Morrill Award), and numerous other National and International awards.

Dr. Low received his B.S. in Chemistry from Brigham Young University (1971) and his Ph.D. in Biochemistry from UCSD (1975).